Novel antibacterial compound analogs targeting mycobacterial respiration pathways

Overview

This solution offers a medicinal chemistry capability focused on the design, synthesis, and structure-activity relationship (SAR) optimization of novel antibacterial compounds. Drawing on more than two decades of medicinal chemistry experience, the lab systematically explores analogs of multiple chemical scaffolds—including oxazoles, isoxazoles, thioxazoles, squaramides, and others—that have demonstrated potency against mycobacterial species such as Mycobacterium tuberculosis.

The core value proposition lies in addressing the urgent global need for new tuberculosis therapeutics, particularly those effective against drug-resistant strains. Many of the compounds developed target essential bacterial processes within the respiration pathway, a validated but underutilized area of antibacterial drug discovery. By focusing on respiration targets such as QcrB (a subunit of the cytochrome _bc_1 complex) and ATP synthase, these compounds represent promising leads for partners seeking differentiated mechanisms of action.

Technical specifications

Core capabilities:

• Systematic analog synthesis across multiple chemical scaffolds including oxazoles, isoxazoles, thioxazoles, and squaramides
• Routine in vitro screening to establish SAR trends and guide compound optimization
• Active investigation of mechanism of action (MOA), with many compounds confirmed as respiration pathway inhibitors
• Targeting of validated mycobacterial essential enzymes including QcrB and ATP synthase
• Iterative medicinal chemistry cycles supported by frequent biological screening data

Key differentiators:

• Scaffold diversity across multiple chemical series, reducing single-mechanism risk
• Focus on essential bacterial processes, supporting lower resistance development potential
• Established workflow for SAR-guided analog preparation and evaluation

Technology readiness level

The compounds are at an early-stage research and lead optimization phase. In vitro potency against mycobacteria has been demonstrated for multiple scaffolds, and SAR trends are actively being mapped through ongoing screening. Mechanism of action studies have confirmed respiration pathway targets for many analogs, though broader preclinical validation—including in vivo efficacy, pharmacokinetics, and toxicology—remains to be completed. The platform is well-suited for collaborative partnerships to advance promising leads toward translational development.